Antipsychotics: Past and Future National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998

Schizophrenia Bulletin

Volumn 25, Issue 2, 1999, Pages 395-405

  Dawkins, Karon ^a   Liebermam, Jeffrey A ^a   Lebowitz, Barry D ^b   Hsiao, John K ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antipsychotic drugs; Atypical antipsychotic drugs; Clozapine; Olanzapine; Quetiapine; Risperidone; Typical antipsychotic drugs; Ziprasidone

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; MENTAL HEALTH SERVICE; NEUROLEPTIC MALIGNANT SYNDROME; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; WORKSHOP;

EID: 0032977638     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033387     Document Type: Conference Paper

References (59)

1. Arvanitis, L.A., and Miller, B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry, 42:233-246, 1997.
2. Beasley, C.M. Jr.; Hamilton, S.H.; Crawford, A.M.; Dellva, M.A.; Tollefson, G.D.; Tran, P.V.; Blin, O.; and Beuzin, J.N. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. European Journal of Neuropsychopharmacology, 7(2):125-137, 1997.
3. Beasley, C.M. Jr.; Sanger, T.; Satterlee, W.; Tollefson, G.; Tran, P.; and Hamilton, S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124(1-2):159-167, 1996a.
4. Beasley, C.M. Jr.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T.; and Hamilton, S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14(2):111-123, 1996b.
5. Blin, O.; Azorin, J.M.; and Bouhours, P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology, 16:38-44, 1996.
6. Bondolfi, G.; Dufour, H.; Patris, M.; May, J.P.; Billeter, U.; Eap, C.B.; and Baumann, P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. American Journal of Psychiatry, 155:499-504, 1998.
7. Bradford, D.W.; Chakos, M.H.; Sheitman, B.B.; and Lieberman, J.A. Atypical antipsychotic drugs in treatment-refractory schizophrenia. Psychiatric Annals, 28:618-626, 1998.
8. Breier, A.; Buchanan R.W.; Kirkpatrick, B.; Davis, O.R.; Irish, D.; Summerfelt, A.; and Carpenter, W.T. Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151:20-26, 1994.
9. Buchanan, R.W.; Holstein, C.; and Breier, A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36:717-725, 1994.
10. Campbell, M.; Armenteros, J.L.; Malone, R.P.; Adams, P.B.; Eisenberg, Z.A.; and Overall, J.E. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36:835-843, 1997.
11. Ceskova, E., and Svesta, J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry, 26:121-124, 1993.
12. Chakos, M.H.; Mayerhoff, D.I.; Loebel, A.D.; Alvir, J.M.J.; and Lieberman, J.A. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacology Bulletin, 28(1):81-86, 1992.
13. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993 [published erratum appears in Journal of Clinical Psychopharmacology, 13:149, 1993].
14. Claus, A.; Bollen, J.; DeCuyer, H.; Eneman, M.; Peuskens, J.; and Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85:295-305, 1992.
15. Cole, J.O.; Goldberg, S.C.; and Davis, J.M. Drugs in the treatment of psychosis: Controlled studies. In: Solomon, P., ed. Psychiatric Drugs. New York, NY: Grune & Stratton, 1966. pp. 153-180.
16. Cole, J.O.; Goldberg, S.C.; Klerman, G.L.; and the National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia: Effectiveness. Archives of General Psychiatry, 10:246-261, 1964.
17. Conley, R.R.; Tamminga, C.A.; Bartko, J.J.; Richardson, C.; Peszke, M.; Lingle, J.; Hegerty, J.; Love, R.; Gournaris, B.A.; and Zaremba, S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155:914-920, 1998.
18. Evans, D.A.P.; Maghoub, A.; Sloan, T.P.; Idle, J.R.; and Smith, R.L. A family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. Journal of Medical Genetics, 17:102-105, 1980.
19. Fann, W.E.; Lake, C.R.; and Majors, L.F. Thioridazine in neurotic, anxious, and depressed patients. Psychosomatics, 15(3):117-121, 1974.
20. Freedman, B. Equipoise and the ethics of clinical research. New England Journal of Medicine, 317:141-145, 1987.
21. Green, M.F.; Marshall, B.D.; Wirshing, W.C.; Ames, D.; Marder, S.R.; McGurk, S.; Kern, R.S.; and Mintz, J. Does risperidone improve working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154:799-804, 1997.
22. Harrigan, E.; Morrissey, M.; Buffenstein, A.; and the Ziprasidone Working Group. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/ schizoaffective disorder. [Abstract]. European Psychiatry, 11(Suppl. 4):112S, 1996.
23. Heinrich, K.; Klieser, E.; Lehman, E.; Kinzler, E.; and Hruschka, H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: A double-blind, randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18(1):129-137, 1994.
24. Hong, C.J.; Chen, J.Y.; Chiu, H.J.; and Sim, C.B. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. International Clinical Psychopharmacology, 12:123-130, 1997.
25. Hoyberg, O.J.; Fensbo, C.; Remvig, J.; Lingjaerde, O.; Sloth-Nielson, M.; and Salvesen, I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica, 85:395-402, 1993.
26. Kane, J.M. Tardive dyskinesia: Epidemiological and clinical presentation. In: Bloom, F.E., and Kupfer, D.J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995. pp. 1485-1495.
27. Kane, J.M.; Honigfeld, G.; Singer, J.; Meltzer, H.Y.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45:789-796, 1988.
28. Kane, J.M., and Marder, S.R. Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19(2):287-302, 1993.
29. Kane, J.M.; Marder, S.R.; Schooler, N.R.; Wirshing, W.C.; Umbricht, D.; Baker, R.W.; Wirshing, D.A.; Safferman, A.; Ganguli, R.; and Borenstein, M. Clozapine and haloperidol in moderately refractory schizophrenia: A six month double-blind comparison. Archives of General Psychiatry, in press.
30. Keefe, R.S.E.; Silva, S.G.; Perkins, D.O.; and Lieberman, J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin, 25(2):201-222, 1999.
31. Klieser, E.; Lehman, E.; Kinzler, E.; Wurtham, C.; and Heinrich, K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology, 15(Suppl. 1):45S-51S, 1995.
32. Kumra, S.; Frazier, J.A.; Jacobsen, L.K.; McKenna, K.; Gordon, C.T.; Lenane, M.C.; Hamburger, S.D.; Smith, A.K.; Albus, K.E.; Alaghband-Rad, J.; and Rapoport, J.L. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Archives of General Psychiatry, 53:1090-1097, 1996.
33. Kumra, S.; Jacobsen, L.K.; Lenane, M.; Smith, A.; Lee, P.; Malanga, C.J.; Karp, B.I.; Hamburger, S.; and Rapoport, J.L. Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 37:221-227, 1998.
34. Lehman A.F.; Steinwachs, D.M.; and the co-investigators of the PORT Project. At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998.
35. Levine, R.J. Uncertainty in clinical research. Law, Medicine, and Health Care, 16:174-182, 1988.
36. Levine, R.J. Randomized clinical trials: Ethical considerations. In: Bittar, E.E., and Bittar, N., eds. Principles of Medical Biology. Vol. 1A. Greenwich, CT: JAI Press, 1994. pp. 37-63.
37. Marder, R.S., and Meibach, R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151(6):825-835, 1994.
38. McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Lee, N.C.; Heninger, G.R.; and Price, L.H. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51(4):302-308, 1994.
39. Meltzer, H.Y., and Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. American Journal of Psychiatry, 152:183-190, 1995.
40. Min, S.K.; Rhee, C.S.; Kim, C.E.; and Kang, D.Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial. Yonsei Medical Journal, 34:179-190, 1993.
41. O'Connor, R.; Harrigan, E.; Heym, J.; Ko, G.; and Chandler, L. "The efficacy and safety profile of a new antipsychotic, ziprasidone." Poster presentation at Association of European Psychiatrists, London, England, July 1996.
42. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychology Reports, 10:799-812, 1962.
43. Paulsen, J.S.; Caligiuri, M.P.; Palmer, B.; McAdams, L.A.; and Jeste, D.V. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study. Psychopharmacology, 123:307-314, 1996.
44. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. British Journal of Psychiatry, 166:712-726, 1995.
45. Peuskens, J., and Link, C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica, 96(4):265-273, 1997.
46. Pickar, D.; Owen, R.R.; Litman, R.E.; Konicki, E.; Gutierrez, R.; and Rapoport, M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Archives of General Psychiatry, 49(5):345-353, 1992.
47. Pollock, B.G.; Mulsant, B.H.; Sweet, R.A.; Rosen, J.; Altieri, L.P.; and Perel, J.M. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacology Bulletin, 31(2):327-332, 1995.
48. Purdon S.E., and the Canadian Cognition and Outcome Study Group. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Schizophrenia Research, 29(1,2):152-153, 1998.
49. Revicki, D.A.; Luce, B.R.; Weschler, J.M.; Brown, R.E.; and Adler, M.A. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41:850-854, 1990.
50. Rosenheck, R.; Cramer, J.; Xu, W.; Thomas, J.; Henderson, W.; Frisman, L.; Fye, C.; and Charney, D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337:809-815, 1997.
51. Salzman, C. Treatment of agitation in the elderly. In: Meltzer, H.Y., ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press, 1987. pp. 1167-1176.
52. Sanger, T.M.; Lieberman, J.A.; Tohen M.; Grundy, S.; Beasley, C.; and Tollefson, G.D. Olanzapine versus haloperidol in first-episode psychosis. American Journal of Psychiatry, 156:79-87, 1999.
53. Schneider, L.S.; Olin, J.T.; Lyness, S.A.; and Chui, H.C. Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of the American Geriatric Society, 45:923-928, 1997.
54. Small, J.G.; Hirsch, S.R.; Arvanitis, L.A.; Miller, B.G.; and Link, C.G. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Archives of General Psychiatry, 54:549-557, 1997.
55. Sweet, R.A., and Pollock, B.G. New atypical antipsychotics: Experience and utility in the elderly. Drugs and Aging, 12(2): 115-127, 1998.
56. Tollefson, G.D.; Beasley, C.M. Jr.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A.; and Thieme, M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154:457-465, 1997.
57. Tollefson, G.D.; Sanger, T.M.; Lu, Y.; and Thieme, M.E. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry, 55:250-258, 1998.
58. Tran, P.V.; Hamilton, S.H.; Kuntz, A.J.; Potvin, J.H.; Andersen, S.W.; Beasley, C.J.; and Tollefson, G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17(5):407-418, 1997.
59. Woerner, M.G.; Alvir, J.M.J.; Saltz, B.; Lieberman, J.; and Kane, J.M. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. American Journal of Psychiatry, 155:1521-1528, 1998.